Correlation of Bcl-2 and p53 Expression in Primary Breast Tumors and Corresponding Metastatic Lymph Nodes

Banu Arun, Gokhan Kilic, Charles Yen, Barbara Foster, Denise Yardley, Richard Gaynor, Raheela Ashfaq

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

BACKGROUND. The p53 tumor suppressor gene product participated in G1 cell cycle arrest or cell death. Loss of function was associated with poor outcome in patients with breast carcinoma. bcl-2 prevented apoptosis induced by c-myc or growth factor deprivation. High bcl-2 expression in breast tumor tissue specimens appears to be associated with favorable prognostic factors. However, Bcl-2 and p53 expression in primary tumor tissue specimens versus metastatic lymph node specimens in breast carcinoma has not been studied. The current study compared Bcl-2 and p53 expression in primary breast carcinoma tissue specimens with Bcl-2 and p53 expression in axillary lymph node specimens. METHODS. Primary breast tumor and corresponding axillary metastatic lymph node tissue specimens were obtained from 60 patients with breast carcinoma. They were evaluated for the presence of Bcl-2 and p53 expression by immunohistochemistry using standard methods. RESULTS. Bcl-2 expression in primary tumor tissue specimens (53%) was correlated with Bcl-2 expression in metastatic lymph node specimens (50%; Pearson correlation = 0.656). p53 expression in primary tumor specimens (72%) was correlated with p53 expression in metastatic lymph node specimens (60%; Pearson correlation = 0.800). A significant inverse correlation also was found between p53 and Bcl-2 expression in primary breast tumor tissue specimens (Pearson correlation = -0.310). CONCLUSIONS. The current study suggested that Bcl-2 and p53 expression in axillary metastatic lymph node specimens is correlated with Bcl-2 and p53 expression in the primary tumor tissue specimens. The prognostic and predictive value of Bcl-2 and p53 expression in axillary lymph node metastasis in patients with breast carcinoma needs to be further evaluated in larger trials with longer follow-up.

Original languageEnglish (US)
Pages (from-to)2554-2559
Number of pages6
JournalCancer
Volume98
Issue number12
DOIs
StatePublished - Dec 15 2003
Externally publishedYes

Fingerprint

Lymph Nodes
Breast Neoplasms
Neoplasms
G1 Phase Cell Cycle Checkpoints
Tumor Suppressor Genes
Intercellular Signaling Peptides and Proteins
Cell Death
Immunohistochemistry
Apoptosis
Neoplasm Metastasis

Keywords

  • Bcl-2
  • Breast carcinoma
  • Lymph nodes
  • p53
  • Prognostic marker

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Correlation of Bcl-2 and p53 Expression in Primary Breast Tumors and Corresponding Metastatic Lymph Nodes. / Arun, Banu; Kilic, Gokhan; Yen, Charles; Foster, Barbara; Yardley, Denise; Gaynor, Richard; Ashfaq, Raheela.

In: Cancer, Vol. 98, No. 12, 15.12.2003, p. 2554-2559.

Research output: Contribution to journalArticle

Arun, B, Kilic, G, Yen, C, Foster, B, Yardley, D, Gaynor, R & Ashfaq, R 2003, 'Correlation of Bcl-2 and p53 Expression in Primary Breast Tumors and Corresponding Metastatic Lymph Nodes', Cancer, vol. 98, no. 12, pp. 2554-2559. https://doi.org/10.1002/cncr.11853
Arun, Banu ; Kilic, Gokhan ; Yen, Charles ; Foster, Barbara ; Yardley, Denise ; Gaynor, Richard ; Ashfaq, Raheela. / Correlation of Bcl-2 and p53 Expression in Primary Breast Tumors and Corresponding Metastatic Lymph Nodes. In: Cancer. 2003 ; Vol. 98, No. 12. pp. 2554-2559.
@article{b6d00ec5e032462cba282b9065be79c3,
title = "Correlation of Bcl-2 and p53 Expression in Primary Breast Tumors and Corresponding Metastatic Lymph Nodes",
abstract = "BACKGROUND. The p53 tumor suppressor gene product participated in G1 cell cycle arrest or cell death. Loss of function was associated with poor outcome in patients with breast carcinoma. bcl-2 prevented apoptosis induced by c-myc or growth factor deprivation. High bcl-2 expression in breast tumor tissue specimens appears to be associated with favorable prognostic factors. However, Bcl-2 and p53 expression in primary tumor tissue specimens versus metastatic lymph node specimens in breast carcinoma has not been studied. The current study compared Bcl-2 and p53 expression in primary breast carcinoma tissue specimens with Bcl-2 and p53 expression in axillary lymph node specimens. METHODS. Primary breast tumor and corresponding axillary metastatic lymph node tissue specimens were obtained from 60 patients with breast carcinoma. They were evaluated for the presence of Bcl-2 and p53 expression by immunohistochemistry using standard methods. RESULTS. Bcl-2 expression in primary tumor tissue specimens (53{\%}) was correlated with Bcl-2 expression in metastatic lymph node specimens (50{\%}; Pearson correlation = 0.656). p53 expression in primary tumor specimens (72{\%}) was correlated with p53 expression in metastatic lymph node specimens (60{\%}; Pearson correlation = 0.800). A significant inverse correlation also was found between p53 and Bcl-2 expression in primary breast tumor tissue specimens (Pearson correlation = -0.310). CONCLUSIONS. The current study suggested that Bcl-2 and p53 expression in axillary metastatic lymph node specimens is correlated with Bcl-2 and p53 expression in the primary tumor tissue specimens. The prognostic and predictive value of Bcl-2 and p53 expression in axillary lymph node metastasis in patients with breast carcinoma needs to be further evaluated in larger trials with longer follow-up.",
keywords = "Bcl-2, Breast carcinoma, Lymph nodes, p53, Prognostic marker",
author = "Banu Arun and Gokhan Kilic and Charles Yen and Barbara Foster and Denise Yardley and Richard Gaynor and Raheela Ashfaq",
year = "2003",
month = "12",
day = "15",
doi = "10.1002/cncr.11853",
language = "English (US)",
volume = "98",
pages = "2554--2559",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Correlation of Bcl-2 and p53 Expression in Primary Breast Tumors and Corresponding Metastatic Lymph Nodes

AU - Arun, Banu

AU - Kilic, Gokhan

AU - Yen, Charles

AU - Foster, Barbara

AU - Yardley, Denise

AU - Gaynor, Richard

AU - Ashfaq, Raheela

PY - 2003/12/15

Y1 - 2003/12/15

N2 - BACKGROUND. The p53 tumor suppressor gene product participated in G1 cell cycle arrest or cell death. Loss of function was associated with poor outcome in patients with breast carcinoma. bcl-2 prevented apoptosis induced by c-myc or growth factor deprivation. High bcl-2 expression in breast tumor tissue specimens appears to be associated with favorable prognostic factors. However, Bcl-2 and p53 expression in primary tumor tissue specimens versus metastatic lymph node specimens in breast carcinoma has not been studied. The current study compared Bcl-2 and p53 expression in primary breast carcinoma tissue specimens with Bcl-2 and p53 expression in axillary lymph node specimens. METHODS. Primary breast tumor and corresponding axillary metastatic lymph node tissue specimens were obtained from 60 patients with breast carcinoma. They were evaluated for the presence of Bcl-2 and p53 expression by immunohistochemistry using standard methods. RESULTS. Bcl-2 expression in primary tumor tissue specimens (53%) was correlated with Bcl-2 expression in metastatic lymph node specimens (50%; Pearson correlation = 0.656). p53 expression in primary tumor specimens (72%) was correlated with p53 expression in metastatic lymph node specimens (60%; Pearson correlation = 0.800). A significant inverse correlation also was found between p53 and Bcl-2 expression in primary breast tumor tissue specimens (Pearson correlation = -0.310). CONCLUSIONS. The current study suggested that Bcl-2 and p53 expression in axillary metastatic lymph node specimens is correlated with Bcl-2 and p53 expression in the primary tumor tissue specimens. The prognostic and predictive value of Bcl-2 and p53 expression in axillary lymph node metastasis in patients with breast carcinoma needs to be further evaluated in larger trials with longer follow-up.

AB - BACKGROUND. The p53 tumor suppressor gene product participated in G1 cell cycle arrest or cell death. Loss of function was associated with poor outcome in patients with breast carcinoma. bcl-2 prevented apoptosis induced by c-myc or growth factor deprivation. High bcl-2 expression in breast tumor tissue specimens appears to be associated with favorable prognostic factors. However, Bcl-2 and p53 expression in primary tumor tissue specimens versus metastatic lymph node specimens in breast carcinoma has not been studied. The current study compared Bcl-2 and p53 expression in primary breast carcinoma tissue specimens with Bcl-2 and p53 expression in axillary lymph node specimens. METHODS. Primary breast tumor and corresponding axillary metastatic lymph node tissue specimens were obtained from 60 patients with breast carcinoma. They were evaluated for the presence of Bcl-2 and p53 expression by immunohistochemistry using standard methods. RESULTS. Bcl-2 expression in primary tumor tissue specimens (53%) was correlated with Bcl-2 expression in metastatic lymph node specimens (50%; Pearson correlation = 0.656). p53 expression in primary tumor specimens (72%) was correlated with p53 expression in metastatic lymph node specimens (60%; Pearson correlation = 0.800). A significant inverse correlation also was found between p53 and Bcl-2 expression in primary breast tumor tissue specimens (Pearson correlation = -0.310). CONCLUSIONS. The current study suggested that Bcl-2 and p53 expression in axillary metastatic lymph node specimens is correlated with Bcl-2 and p53 expression in the primary tumor tissue specimens. The prognostic and predictive value of Bcl-2 and p53 expression in axillary lymph node metastasis in patients with breast carcinoma needs to be further evaluated in larger trials with longer follow-up.

KW - Bcl-2

KW - Breast carcinoma

KW - Lymph nodes

KW - p53

KW - Prognostic marker

UR - http://www.scopus.com/inward/record.url?scp=0345098484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345098484&partnerID=8YFLogxK

U2 - 10.1002/cncr.11853

DO - 10.1002/cncr.11853

M3 - Article

VL - 98

SP - 2554

EP - 2559

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -